3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
13
Brain Neoplasms
12
Neuroblastoma
11
Gliosarcoma
7
Astrocytoma
7
Oligodendroglioma
5
Glioma
5
Medulloblastoma
4
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Wilms Tumor
2
Spinal Cord Neoplasms
2
Rhabdoid Tumor
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Optic Nerve Glioma
2
Lung Neoplasms
2
Familial ependymoma
2
Diffuse Intrinsic Pontine Glioma
2
Dendritic Cell Sarcoma, Interdigitating
2
Choroid Plexus Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Interventions
Temozolomide
2
Oncolytic Virotherapy
2
vorasidenib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Vorinostat
1
Vincristine
1
Valproic Acid
1
Thiotepa
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Erlotinib Hydrochloride
1
Cisplatin
1
Busulfan
1
Bone Marrow Transplantation
1
Antibodies, Monoclonal
1
Aminolevulinic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors
×
Vorinostat
×
CNS
×
Clear all
NCT03561259
2023-02-16
OPTIMUM
Jubilant DraxImage Inc.
Phase 2
Unknown
60 enrolled